Real-time cell observation platform could revolutionize cancer drug discovery

Cancer drug development is broken in a specific, measurable way: most compounds that show promise in the laboratory never make it to patients. The failure rate is staggering. Scientists have spent years asking why, and the answer keeps pointing to the same problem—the tools they use to test drugs are too crude. They kill the cells to study them. They freeze them in time. They measure only the endpoint, missing everything that happens in between.

Now there is a platform that changes that equation. It watches cells live. It measures their behavior continuously, in real time, without killing them or fixing them or breaking them apart. The implications are being discussed seriously by oncologists and biotech entrepreneurs who understand what this could mean for cancer research and, eventually, for patients.

Dr. Shyam Aggarwal, who chairs the Department of Medical Oncology at Sir Ganga Ram Hospital in New Delhi, laid out the case plainly on Saturday. Real-time observation of living cells could help researchers understand how those cells actually respond to experimental drugs. It could accelerate the detection of subtle biochemical shifts that signal whether a therapy might work. It could identify promising candidates faster, during the preclinical stage, before the enormous expense and time of human trials. Beyond that, Aggarwal noted, understanding precision oncology through comprehensive genome profiling and minimal residual disease detection could help physicians tailor cancer treatment to individual patients—moving medicine away from one-size-fits-all toward something genuinely personalized.

Parmita Mishra, an Indian-origin biotech entrepreneur based in San Francisco, founded Precigenetics to build exactly this kind of platform. She frames the shift in stark terms: researchers have been conducting biological autopsies. They observe cells at one moment in time, after the experiment is over, after the cells are dead. With continuous measurement, she argues, scientists can watch cells behave over time, uncovering patterns and responses that were simply invisible before. The implications extend far beyond cancer—into immunology, neuroscience, rare diseases, and regenerative medicine.

The conventional laboratory approach requires sacrifice. Cells must be stained with dyes, fixed in place, or lysed—broken open—before analysis can begin. Each of these steps is destructive. You get a snapshot, not a film. You see the endpoint, not the journey. The platform Precigenetics has developed monitors living biology continuously, allowing researchers to study cellular behavior as it unfolds rather than reconstructing it from a single frozen moment.

The stakes are concrete. India reported an estimated 1.4 million new cancer cases in 2022, according to data from the International Agency for Research on Cancer. The Indian Council of Medical Research projects that this burden will only grow over the coming decade. The country faces a rising tide of cancer diagnosis, and the tools for developing effective treatments remain inadequate. Most oncology drug candidates that enter clinical development ultimately fail before reaching patients. Scientists increasingly understand that this failure rate stems not from bad luck or bad chemistry, but from the fundamental limitations of how they test drugs in the first place.

A platform that lets researchers watch cells respond to candidate drugs in real time, without destroying them, addresses that limitation directly. It does not solve cancer. It does not guarantee that new drugs will work. But it removes one major barrier between laboratory discovery and clinical reality—the gap between how cells behave in a dish and how they actually behave when alive. For a field where most candidates fail, even a modest improvement in the ability to predict which drugs will work could reshape the landscape of drug development, accelerate the pace of discovery, and ultimately bring effective treatments to patients faster.